Pacira Q2 revenue $192.4M (+6% YoY); divests iovera° to Zimmer Biomet for up to $140M

Pacira BioSciences, Inc.

Q2 total revenue $192.4M (+6% YoY); GAAP net income $4.7M ($0.12 EPS) vs net loss of $4.8M in Q2 2025.
EXPAREL net sales $147.8M (+3% YoY); ZILRETTA $32.6M (+4%); iovera $6.8M (+22%).
Completed divestiture of iovera° to Zimmer Biomet for up to $140M ($70M upfront + milestones); closed July 31, 2026.
UnitedHealthcare now provides separate reimbursement for EXPAREL, covering ~40M lives.
Updated FY2026 total revenue guidance to $735M-$760M (from $745M-$770M) reflecting iovera divestiture.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.